 |
AcelRx is
an early stage company developing a novel drug delivery platform
technology.
 |
351 Galveston Drive
Redwood City, CA 94063
Phone:650.216.3518
Fax: 650.216.6500 |
 |
 |
Advion is leading manufacturer of microfluidics systems for chemistry and biochemistry applications, and operates the scientific leader in LC/MS and immunoassay services. Advion was acquired by Quintiles in October 2011, and Advion's product business was spun-off to shareholders before the acquisition.
|
19 Brown Road
Ithaca, NY 14850 USA
Phone:
607.266.0665
Fax:
607.266.0749 |
|
 |
Avidia is focused on discovering and developing a new class of human therapeutic proteins called Avimers™ which are derived from a family of small, naturally-occurring protein binding domains. The company was acquired by Amgen in September of 2006.
|
2450 Bayshore Parkway
Suite 200
Mountain View CA 94043
Phone:
650.404.2000
Fax:
650.404.2001 |
|
 |
Celula is developing a prenatal diagnostic test based on isolation of fetal cells from the mothers blood.
|
5820 Nancy Ridge Drive, Suite 100
San Diego, CA 92121
Phone: 858.875.8800
Fax: 858.875.8805 |
|
 |
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on its DETERx™ platform technology, a proprietary formulation technology that makes improved, tamper-resistant forms of medications which are prone to abuse.
The Company currently has two product candidates in clinical development: COL-003, a tamper-resistant form of oxycodone (the active ingredient in OxyContin®), which is entering Phase 3 development; and COL-172, a tamper-resistant form of oxymorphone, the active ingredient in Opana®. Both products have received Fast Track designation by the FDA due to their potential to address a major public health issue.
|
400 Highland Corporate Drive
Cumberland, RI 02864
Phone: 401.762.2000 |
|
 |
Concert Pharmaceuticals was founded to utilize deuterium substitution to improve existing drugs.
|
99 Hayden Avenue, Suite 500
Lexington, MA 02421
Phone: 781.860.0045
Fax: 781.860.8923 |
|
 |
Dicerna Pharmaceuticals is developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism. Dicerna’s intellectual property covers double stranded RNA molecules 26-30 base pairs in length, which are generally more potent in inducing RNA interference than the conventional 19-23 base pair sequences.
|
480 Arsenal Street
Building 1, Suite 120
Watertown MA 02472
Phone: 617.621.8097 |
|
 |
Proprietary assays
for high throughput screening and other applications in drug discovery.
|
42501 Albrae Street
Fremont, CA 94538
Phone:
866.448.4864
Fax:
510.979.1650 |
|
 |
Dow is a leading formulator of prescription drugs for dermatology applications. The company was sold to Valeant Pharmaceuticals International (NYSE: VRX) in December 2008.
|
1330 Redwood Way
Petaluma, CA 94954-1169
Phone:
707.793.2600
Fax: 707.793.0145 |
|
 |
Genocea Biosciences has developed a proprietary technology platform for identifying T-cell vaccine products to treat diseases that are unserved or underserved by existing technology.
|
Cambridge Discover Park
100 Acorn Park Drive, 5th Floor
Cambridge, MA 02140
Phone: 617.876.8191
Fax: 617.876.8192 |
|
 |
Hansen Medical introduces
the power of instinctive catheter movement. This revolutionary technology
is designed to deliver precise three-dimensional catheter control
to complex interventional procedures.
|
[NASDAQ: HNSN] |
|
800 East Middlefield Road
Mountain View, CA 94043
Phone:650.404.5800
Fax: 650.404.5901 |
|
 |
The company seeks to correct knee misalignment through an instrumented system to guide a reproducible and precise surgical technique called high tibial osteotomy (“HTO”). iBalance was acquired by Arthrex in March, 2010.
|
4900 Nautilus Ct, Suite 100
Boulder, CO 80503
Phone:
303.381.6333 |
|
 |
InteKrin is developing an insulin sensitizing drug called INT131, which is in Phase 2b development for treatment of Type II diabetes. As a new chemical class that affects its target in a novel way, INT131 was designed to avoid the characteristic adverse effects of other insulin sensitizers, such as weight gain or edema. In animal studies and Phase 2a trials, the drug showed strong efficacy without these adverse effects.
|
4300 El Camino Real, Suite 201
Los Altos, CA 94022
Phone: 650.941.5501
Fax: 866.286.2242 |
|
 |
KAI's lead product candidate KAI-4169, is a novel agent being developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease who are on dialysis. In July 2012, KAI was acquired by Amgen for $315 million.
|
270 Littlefield Avenue
South San Francisco, CA 94080-6924
Phone:
650.244.1100 |
|
 |
MAKO Surgical designs and sells an advanced robotic-arm solution, together with proprietary implants, for minimally invasive orthopedic knee procedures. MAKO plasty procedures preserve more bone and produce less pain and quicker recovery for the patient than total knee replacement procedures, and are easier for the surgeon to accomplish accurately than unicondylar knee implants. The system is FDA approved, and MAKO is shipping it as well as implants to resurface the medical and patella-femoral compartments of the knee, which are the bearing surfaces most often affected in knee disease.
|
[NASDAQ: MAKO] |
|
2555 Davie Road
Ft. Lauderdale, FL 33317
Phone:954.927.2044
Fax:954.927.0446 |
|
 |
Improved administration
of inhaled drugs, including a version of budesonide, the leading
nebulized steroid for small children. MAP’s version of budesonide
promises to decrease administration time significantly, allowing
MAP’s version to potentially become the standard budesonide
therapy for these patients.
|
[NASDAQ: MAPP] |
|
2400 Bayshore Parkway, Suite 200
Mountain View, CA 94043
Phone:650.386.3100
Fax:650.386.3101 |
|
 |
Medivance is the leading company in therapeutic hypothermia. It is the only company to produce a practical solution that uses consumables and equipment for the non-invasive production of therapeutic hypothermia. The Company was acquired by Bard [NYSE: BCR] in October of 2011.
|
321 South Taylor Avenue, Suite 200
Louisville, CO 80027
Phone:
303.926.1917
Fax: 303.926.1924 |
|
 |
High-density, fully-custom microarrays for any sequences of any genome, up to 60-mers in length. The company was purchased by Roche Holdings [RO.SW] in 2007.
|
504 South Rosa Road
Madison, WI 53719
Phone:
608.218.7600
Fax:
608.218.7601 |
|
 |
NovaCardia is a product-focused pharmaceutical company developing and commercializing a portfolio of novel small molecule drugs with an initial focus on the acute cardiac care marketplace. The company was acquired by Merck & Co. in September of 2007.
|
12651 High Bluff Drive
Suite 200
San Diego, CA 92130
Phone:858.509.0455
Fax:858.509.0456 |
|
 |
Novasys Medical's first product, the Renessa® System, is a proprietary, FDA-approved, non-surgical treatment for female stress urinary incontinence (SUI), a disorder that affects over 15 million women in the United States. The Renessa System uses radiofrequency energy to remodel the patient’s own collagen in the bladder and urethra, firming the tissue and reducing incontinence episodes. The treatment offers women and their physicians a new, non-incisional treatment option for SUI. It is performed painlessly in a doctor’s office under local anesthesia, in less than an hour.
|
39684 Eureka Drive
Newark, CA 94560
Phone:510.226.4060
Fax:510.353.0524 |
|
 |
Proteon Therapeutics’
Type I Elastase permanently dilates blood vessels. It is being developed
to enlarge potential hemodialysis access sites in renal failure
patients, increasing the number of possible access sites and prolonging
the life of new access sites.
|
4420 Madison Avenue
Suite 180
Kansas City, MO 64111
Phone:
816.531.0028
Fax:
816.531.3079 |
|
 |
SI Bone has developed proprietary surgical devices to fixate the sacroiliac (SI) joint using minimally invasive techniques. Orthopedists are increasingly realizing that sacroiliac joint arthritis is responsible for a large percentage of lower back pain. Conventional methods to treat and fuse the SI joint are highly invasive.
|
3055 Olin Avenue
Ste. 2200
San Jose, CA 95128
Phone: 408.207.0700
Fax: 408.557.8312 |
|
 |
Sirtris is focused on discovering and developing proprietary, orally available drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Its drug candidates are designed to mimic certain beneficial health effects of calorie restriction, without requiring a change in eating habits, by activation of sirtuins, a recently discovered class of enzymes that control the aging process. The company was acquired by GlaxoSmithKline for $720 million in June 2008.
|
[NASDAQ: SIRT] |
|
200 Technology Square
Cambridge, MA 02139
Phone: 617.252.6920
Fax: 617.252.6924 |
|
 |
Spinal Motion is in late
stage US clinical trials of its artificial discs for treating patients
with degenerative disc disease in the lumbar and cervical spine.
Its products were invented in South Africa and are on the market
there with excellent results.
|
201 San Antonio Circle
Suite 115, Building B
Mountain View, CA 94040
Phone: 650.947.3472
Fax: 650.947.3473 |
|
 |
Sutro Biopharma uses its cell-free expression technology to discover and produce proteins that cannot be expressed in traditional cell-based systems, including proteins with non-natural amino acids.
|
310 Utah Ave
Suite 150
South San Francisco, CA 94080
Phone: 650.392.8412
Fax: 650.872.8924 |
|
 |
Tetraphase Pharmaceuticals, Inc is attempting to discover and develop novel tetracycline-based antibiotic drugs. The company is based on the first complete synthesis of the tetracycline scaffold, which allows medicinal chemists to synthesize tetracycline derivatives that previously were impossible to create.
|
480 Arsenal Street, Ste 110
Watertown, MA 02472
Phone: 617.715.3600
Fax: 617.926.3557 |
|
 |
The leading company in Engineered Drug Transport(tm), which uses active transport systems to improve the oral absorption, distribution, and pharmacokinetics of existing active drug ingredients. Its lead drug has completed three positive Phase 3 clinical trials, and a second drug has completed a positive Phase 2a clinical trial, and a third drug has completed a positive Phase 1 clinical trial.
|
[NASDAQ: XNPT] |
|
3410 Central Expressway
Santa Clara, CA 95051
Phone: 408.616.7200
Fax: 408.616.7210 |
About Us